Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Acro Biomedical (ACBM) Interest Expenses (2018 - 2025)

Acro Biomedical has reported Interest Expenses over the past 8 years, most recently at $2710.0 for Q3 2025.

  • Quarterly results put Interest Expenses at $2710.0 for Q3 2025, up 141.32% from a year ago — trailing twelve months through Dec 2025 was $6025.0 (up 38.86% YoY), and the annual figure for FY2024 was $4339.0, up 35.34%.
  • Interest Expenses for Q3 2025 was $2710.0 at Acro Biomedical, up from $1948.0 in the prior quarter.
  • Over the last five years, Interest Expenses for ACBM hit a ceiling of $2710.0 in Q3 2025 and a floor of -$3155.0 in Q4 2021.
  • Median Interest Expenses over the past 5 years was $839.0 (2023), compared with a mean of $851.0.
  • Peak annual rise in Interest Expenses hit 467.57% in 2021, while the deepest fall reached 246.4% in 2021.
  • Acro Biomedical's Interest Expenses stood at -$3155.0 in 2021, then soared by 124.94% to $787.0 in 2022, then grew by 6.61% to $839.0 in 2023, then skyrocketed by 43.62% to $1205.0 in 2024, then surged by 124.9% to $2710.0 in 2025.
  • The last three reported values for Interest Expenses were $2710.0 (Q3 2025), $1948.0 (Q2 2025), and $1367.0 (Q1 2025) per Business Quant data.